COVID-19 Diagnostics Market Report by Product Type, Sample Type, Test Type (Molecular Testing, Antigen-based Testing, Antibody Testing, and Others), Mode (Point-of-Care, Non-Point-of-Care ), End Use, and Region 2024-2032
코로나19 진단 시장 규모는 2023년 630억 달러에 달했습니다. IMARC Group은 2032년까지 이 시장이 306억 달러에 달할 것으로 예측됩니다.
코로나19 진단은 개인의 바이러스 감염의 유무를 검출하기 위해 수행되는 임상 검사를 말합니다. COVID-19는 새로 발견된 인간 짐승 공통 감염 코로나 바이러스에 의해 유발된 감염입니다. 일반적인 증상으로는 발열, 피로, 마른 기침, 호흡 곤란, 인두통, 신체 통증 등이 있습니다. 바이러스 감염은 보통 역전사효소-중합효소 연쇄반응(RT-PCR), 항원검사, 항체검사에 의해 진단됩니다. 이러한 검사는 상인두(NP), 구강인두(OP), 비강 봉제액, 타액, 혈액에서 샘플을 채취하기 위한 시약 및 키트를 사용합니다. 병원, 연구소, 클리닉, 연구 기관, 진단센터 등에서 널리 사용됩니다.
코로나 바이러스 감염의 갑작스러운 발생과 세계의 COVID-19의 증례 수가 우려할 정도로 증가하는 것은 시장 성장의 긍정적인 전망을 창출하는 주요 요인 중 하나입니다. 일상적인 사례 수의 지속적인 증가는 환자에게 조기 치료를 제공하기 위해 신속하고 종합적인 검사를위한 진단 검사의 광범위한 채택으로 이어지고 있습니다. 이에 따라 대량검사나 분자진단 수요가 증가하고 있는 것이 시장의 성장에 기여하고 있습니다. 게다가 새로운 항체 검사 키트나 혈청 검사 키트의 발매 등 다양한 제품 혁신도 성장을 가속하는 요인이 되고 있습니다. 전통적으로 사용되는 검사 키트와 비교하여 이러한 변형은 시간이 걸리지 않으며 정확한 결과를 얻기 위해 소프트웨어 기반 프로그램과 통합할 수 있습니다. 그 밖에 COVID-19 감염의 추가 확대를 막기 위한 정부의 호의적인 정책의 실시와, 특히 신흥 경제국가의 헬스케어 인프라의 대폭적인 개선 등이 시장 성장을 가속할 것으로 예측되고 있습니다.
이 보고서에서 다루는 주요 질문
- 2023년 세계의 코로나19 진단 시장 규모는?
- 세계의 코로나19 진단 시장에 대한 COVID-19의 영향은?
- 세계의 코로나19 진단 시장을 견인하는 주요 요인은?
- 세계의 코로나19 진단 시장의 제품 유형별 내역은?
- 세계의 코로나19 진단 시장의 샘플 유형별 내역은?
- 세계의 코로나19 진단 시장의 검사 유형별 내역은?
- 세계의 코로나19 진단 시장의 모드별 내역은?
- 코로나19 진단 시장의 최종 용도별 내역은?
- 코로나19 진단 시장의 주요 지역은?
- 코로나19 진단 시장의 주요 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 코로나19 진단 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 제품 유형별
제7장 시장 내역 : 샘플 유형별
제8장 시장 분석 : 검사 유형별
- 분자(RT-PCR) 검사
- 항원 검사
- 항체(혈청학) 검사
- 기타
제9장 시장 분석 : 모드별
- 포인트 오브 케어(PoC)
- 비포인트 오브 케어(비PoC)
제10장 시장 내역 : 최종 용도별
제11장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제12장 SWOT 분석
제13장 밸류체인 분석
제14장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제15장 가격 분석
제16장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abbott Laboratories
- Becton Dickinson and Company
- bioMerieux SA
- Bio-Rad Laboratories
- Danaher Corporation
- F. Hoffman-La Roche Ltd.(Roche Holding AG)
- Luminex Corporation
- PerkinElmer Inc.
- Quest Diagnostics Incorporated
- Robert Bosch GmbH
- Seegene Inc.
- Siemens Aktiengesellschaft
- Thermo Fisher Scientific Inc.
BJH
The global COVID-19 diagnostics market size reached US$ 63.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 30.6 Billion by 2032.
COVID-19 diagnostics refer to the clinical tests conducted to detect the presence of the viral infection among individuals. COVID-19 is an infectious disease caused by the newly discovered zoonotic coronavirus. Some common symptoms include fever, fatigue, dry cough, shortness of breath, sore throat and body aches. The viral infection is usually diagnosed through reverse transcriptase-polymerase chain reaction (RT- PCR), antigen-based and antibody testing. These tests use reagents and kits to obtain the sample from nasopharyngeal (NP), oropharyngeal (OP) and nasal swabs, human saliva or blood. They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.
The sudden outbreak of coronavirus disease and an alarming increase in the number of COVID-19 cases across the globe are among the key factors creating a positive outlook for the market growth. The continuous rise in the number of daily cases has led to the widespread adoption of diagnostic tests for rapid and comprehensive testing to provide early treatment to the patients. In line with this, the increasing demand for mass testing and molecular diagnostics is contributing to the market growth. Additionally, various product innovations, such as the launch of novel antibody and serology test kits for home-testing, are acting as other growth-inducing factors. In comparison to the traditionally used testing kits, these variants are less time-consuming and can be integrated with software-based programs for accurate results. Other factors, including the implementation of favorable government polices to prevent the further spread of COVID-19 infection, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global COVID-19 diagnostics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product type, sample type, test type, mode and end use.
Breakup by Product Type:
Reagents and Kits
Instruments
Others
Breakup by Sample Type:
Nasopharyngeal Swabs
Oropharyngeal Swabs
Nasal Swabs
Blood
Others
Breakup by Test Type:
Molecular (RT-PCR) Testing
Antigen-based Testing
Antibody (Serology) Testing
Others
Breakup by Mode:
Point-of-Care (PoC)
Non-Point-of-Care (Non-PoC)
Breakup by End Use:
Laboratories
Hospitals
Diagnostic Centers and Clinics
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche Ltd. (Roche Holding AG), Luminex Corporation, PerkinElmer Inc., Quest Diagnostics Incorporated, Robert Bosch GmbH, Seegene Inc., Siemens Aktiengesellschaft and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report
- 1. What was the size of the global COVID-19 diagnostics market in 2023?
- 2. What has been the impact of COVID-19 on the global COVID-19 diagnostics market?
- 3. What are the key factors driving the global COVID-19 diagnostics market?
- 4. What is the breakup of the global COVID-19 diagnostics market based on the product type?
- 5. What is the breakup of the global COVID-19 diagnostics market based on the sample type?
- 6. What is the breakup of the global COVID-19 diagnostics market based on the test type?
- 7. What is the breakup of the global COVID-19 diagnostics market based on the mode?
- 8. What is the breakup of the global COVID-19 diagnostics market based on the end use?
- 9. What are the key regions in the global COVID-19 diagnostics market?
- 10. Who are the key players/companies in the global COVID-19 diagnostics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global COVID-19 Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Reagents and Kits
- 6.1.1 Market Trends and Forecast
- 6.2 Instruments
- 6.2.1 Market Trends and Forecast
- 6.3 Others
- 6.3.1 Market Trends and Forecast
7 Market Breakup by Sample Type
- 7.1 Nasopharyngeal Swabs
- 7.1.1 Market Trends and Forecast
- 7.2 Oropharyngeal Swabs
- 7.2.1 Market Trends and Forecast
- 7.3 Nasal Swabs
- 7.3.1 Market Trends and Forecast
- 7.4 Blood
- 7.4.1 Market Trends and Forecast
- 7.5 Others
- 7.5.1 Market Trends and Forecast
8 Market Breakup by Test Type
- 8.1 Molecular (RT-PCR) Testing
- 8.1.1 Market Trends and Forecast
- 8.2 Antigen-based Testing
- 8.2.1 Market Trends and Forecast
- 8.3 Antibody (Serology) Testing
- 8.3.1 Market Trends and Forecast
- 8.4 Others
- 8.4.1 Market Trends and Forecast
9 Market Breakup by Mode
- 9.1 Point-of-Care (PoC)
- 9.1.1 Market Trends and Forecast
- 9.2 Non-Point-of-Care (Non-PoC)
- 9.2.1 Market Trends and Forecast
10 Market Breakup by End Use
- 10.1 Laboratories
- 10.1.1 Market Trends and Forecast
- 10.2 Hospitals
- 10.2.1 Market Trends and Forecast
- 10.3 Diagnostic Centers and Clinics
- 10.3.1 Market Trends and Forecast
- 10.4 Others
- 10.4.1 Market Trends and Forecast
11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Trends and Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Trends and Forecast
- 11.2 Asia-Pacific
- 11.2.1 China
- 11.2.1.1 Market Trends and Forecast
- 11.2.2 Japan
- 11.2.2.1 Market Trends and Forecast
- 11.2.3 India
- 11.2.3.1 Market Trends and Forecast
- 11.2.4 South Korea
- 11.2.4.1 Market Trends and Forecast
- 11.2.5 Australia
- 11.2.5.1 Market Trends and Forecast
- 11.2.6 Indonesia
- 11.2.6.1 Market Trends and Forecast
- 11.2.7 Others
- 11.2.7.1 Market Trends and Forecast
- 11.3 Europe
- 11.3.1 Germany
- 11.3.1.1 Market Trends and Forecast
- 11.3.2 France
- 11.3.2.1 Market Trends and Forecast
- 11.3.3 United Kingdom
- 11.3.3.1 Market Trends and Forecast
- 11.3.4 Italy
- 11.3.4.1 Market Trends and Forecast
- 11.3.5 Spain
- 11.3.5.1 Market Trends and Forecast
- 11.3.6 Russia
- 11.3.6.1 Market Trends and Forecast
- 11.3.7 Others
- 11.3.7.1 Market Trends and Forecast
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Trends and Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Trends and Forecast
- 11.4.3 Others
- 11.4.3.1 Market Trends and Forecast
- 11.5 Middle East and Africa
- 11.5.1 Market Trends and Forecast
- 11.5.2 Market Breakup by Country
12 SWOT Analysis
- 12.1 Overview
- 12.2 Strengths
- 12.3 Weaknesses
- 12.4 Opportunities
- 12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
- 16.3.1 Abbott Laboratories
- 16.3.1.1 Company Overview
- 16.3.1.2 Product Portfolio
- 16.3.1.3 Financials
- 16.3.1.4 SWOT Analysis
- 16.3.2 Becton Dickinson and Company
- 16.3.2.1 Company Overview
- 16.3.2.2 Product Portfolio
- 16.3.2.3 Financials
- 16.3.2.4 SWOT Analysis
- 16.3.3 bioMerieux SA
- 16.3.3.1 Company Overview
- 16.3.3.2 Product Portfolio
- 16.3.3.3 Financials
- 16.3.3.4 SWOT Analysis
- 16.3.4 Bio-Rad Laboratories
- 16.3.4.1 Company Overview
- 16.3.4.2 Product Portfolio
- 16.3.4.3 Financials
- 16.3.4.4 SWOT Analysis
- 16.3.5 Danaher Corporation
- 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
- 16.3.5.3 Financials
- 16.3.5.4 SWOT Analysis
- 16.3.6 F. Hoffman-La Roche Ltd. (Roche Holding AG)
- 16.3.6.1 Company Overview
- 16.3.6.2 Product Portfolio
- 16.3.6.3 Financials
- 16.3.7 Luminex Corporation
- 16.3.7.1 Company Overview
- 16.3.7.2 Product Portfolio
- 16.3.7.3 Financials
- 16.3.7.4 SWOT Analysis
- 16.3.8 PerkinElmer Inc.
- 16.3.8.1 Company Overview
- 16.3.8.2 Product Portfolio
- 16.3.8.3 Financials
- 16.3.8.4 SWOT Analysis
- 16.3.9 Quest Diagnostics Incorporated
- 16.3.9.1 Company Overview
- 16.3.9.2 Product Portfolio
- 16.3.9.3 Financials
- 16.3.9.4 SWOT Analysis
- 16.3.10 Robert Bosch GmbH
- 16.3.10.1 Company Overview
- 16.3.10.2 Product Portfolio
- 16.3.11 Seegene Inc.
- 16.3.11.1 Company Overview
- 16.3.11.2 Product Portfolio
- 16.3.11.3 Financials
- 16.3.12 Siemens Aktiengesellschaft
- 16.3.12.1 Company Overview
- 16.3.12.2 Product Portfolio
- 16.3.12.3 Financials
- 16.3.12.4 SWOT Analysis
- 16.3.13 Thermo Fisher Scientific Inc.
- 16.3.13.1 Company Overview
- 16.3.13.2 Product Portfolio
- 16.3.13.3 Financials
- 16.3.13.4 SWOT Analysis
